Scientists hunt for biomarkers to predict immunotherapy success in melanoma
NCT ID NCT03348891
First seen Apr 18, 2026 · Last updated Jun 15, 2026 · Updated 11 times
Summary
This study involved 60 people with advanced melanoma who were already scheduled to receive immunotherapy drugs (either a single drug or a combination). Researchers collected blood samples and, when possible, tumor samples before and during treatment to look for markers that might predict whether the cancer would shrink or grow. The goal was to better understand why some patients respond well to these treatments while others do not.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHRU Claude HURIEZ
Lille, France
-
CHU Montpellier Saint-Eloi
Montpellier, France
-
Institut Universitaire du Cancer de Toulouse - Oncopole
Toulouse, 31059, France
Conditions
Explore the condition pages connected to this study.